

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Fifty-second report



World Health
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about four to six such reports, costs CHF 150.00/US\$ 180.00 (CHF 105.00/US\$ 126.00 in developing countries). For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int; order online: <http://www.who.int/bookorders>).

W H O T e c h n i c a l R e p o r t S e r i e s
1 0 1 0

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Fifty-second report

This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization



**World Health
Organization**

WHO Expert Committee on Specifications for Pharmaceutical Preparations, fifty-second report
(WHO Technical Report Series, No. 1010)

ISBN 978-92-4-121019-5
ISSN 0512-3054

© World Health Organization 2018

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. WHO Expert Committee on Specifications for Pharmaceutical Preparations, fifty-second report. Geneva: World Health Organization; 2018 (WHO Technical Report Series, No. 1010). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Printed in Italy

Contents

Introduction	1
Open session	2
Introduction to the ECSPP	2
1. General policy	4
1.1 Cross-cutting pharmaceutical quality assurance issues	4
1.2 International collaboration	10
2. Quality control – specifications and tests for <i>The International Pharmacopoeia</i>	14
2.1 Update and workplan	14
2.2 General policy	14
2.3 General chapters	17
2.4 General monographs for dosage forms and associated method texts	17
2.5 Specifications for medicines, including children’s medicines and radiopharmaceuticals	17
3 Quality control – international reference materials (International Chemical Reference Substances and Infrared Reference Spectra)	26
3.1 Report of the custodian centre	26
3.2 Update on International Chemical Reference Substances, including report of the dedicated Expert Committee on Specifications for Pharmaceutical Preparations subgroup on International Chemical Reference Substances	26
3.3 General policy	27
4. Quality control – national laboratories	28
4.1 External Quality Assurance Assessment Scheme	28
4.2 Considerations for requesting analysis of medicines samples and model certificate of analysis	28
4.3 Guidance on testing of “suspect” falsified medicines	29
5. Prequalification of quality control laboratories	30
5.1 Update on the prequalification of quality control laboratories	30
5.2 Update on WHO quality monitoring projects	30
6. Quality assurance – collaboration initiatives	31
6.1 International meetings of world pharmacopoeias	31
6.2 Good pharmacopoeial practices	31
6.3 Inspection guidelines and good practices	33
7. Quality assurance – good manufacturing practices	34
7.1 Guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems	34
7.2 WHO good manufacturing practices: validation, including main principles and specific texts (water, cleaning, computerized systems, qualification of systems and equipment, non-sterile)	34

7.3	Guidance on good practices for desk review for good manufacturing practices, confirmation in lieu of on-site assessment	35
7.4	Update and recommendations from the inspectors' meeting	35
8.	Regulatory guidance	37
8.1	Regulatory requirements on stability testing of active pharmaceutical ingredients and finished pharmaceutical products	37
8.2	Biowaiver list based on the WHO Model List of Essential Medicines	37
8.3	Collaborative procedure for the assessment and accelerated national registration of medicines and vaccines approved by stringent regulatory authorities	39
8.4	Good practices for implementing the collaborative procedures	40
8.5	Good regulatory practices	40
8.6	Quality management systems for national regulatory authorities	41
9.	Prequalification of priority essential medicines and active pharmaceutical ingredients	42
9.1	Update on the prequalification of medicines	42
9.2	Update on the prequalification of active pharmaceutical ingredients	42
10.	Nomenclature, terminology and databases	43
10.1	Definition of "stringent regulatory authority"	43
10.2	Quality assurance terminology	44
10.3	Guidelines and guidance texts adopted by the Committee	44
10.4	International Nonproprietary Names for pharmaceutical substances	44
10.5	Guidance on the graphic representation of pharmaceutical substances	45
11.	Miscellaneous	46
11.1	WHO Department of Essential Medicines and Health Products: Strategic vision	46
12.	Closing remarks	47
13.	Summary and recommendations	48
	Acknowledgements	56
	Annex 1	
	WHO guidelines on good herbal processing practices for herbal medicines	81
	Annex 2	
	Guidelines on good manufacturing practices for the manufacture of herbal medicines	153
	Annex 3	
	Considerations for requesting analysis of medicines samples	179
	Annex 4	
	Model certificate of analysis	187
	Annex 5	
	WHO guidance on testing of "suspect" falsified medicines	193
	Annex 6	
	Good pharmacopoeial practices: Chapter on monographs for compounded preparations	235

Annex 7	
Good pharmacopoeial practices: Chapter on monographs on herbal medicines	241
Annex 8	
Guidelines on heating, ventilation and air-conditioning systems for non-sterile pharmaceutical products	249
Annex 9	
Guidance on good practices for desk assessment of compliance with good manufacturing practices, good laboratory practices and good clinical practices for medical products regulatory decisions	271
Annex 10	
Stability testing of active pharmaceutical ingredients and finished pharmaceutical products	309
Annex 11	
Collaborative procedure in the assessment and accelerated national registration of pharmaceutical products and vaccines approved by stringent regulatory authorities	353



WHO Expert Committee on Specifications for Pharmaceutical Preparations

Geneva, 16–20 October 2017

Members¹

Dr Ibrahim Aljuffali, Riyadh, Saudi Arabia

Dr Joey Gouws, Pretoria, South Africa (*Chair*)

Professor Jin Shaohong, Beijing, People's Republic of China (*Vice-chair*)

Dr C. Michelle Limoli, Silver Spring, MD, USA (*Rapporteur*)

Ms Gugu Nolwandle Mahlangu, Harare, Zimbabwe

Dr Haruhiro Okuda, Tokyo, Japan

Mrs Lynda Paleshnuik, Arnprior, Ontario, Canada

Dr Jitka Sabartova, Prague, Czech Republic

Dr Budiono Santoso, Yogyakarta, Indonesia (*Rapporteur*)

Dr Luisa Stoppa, Rome, Italy

Temporary advisers²

Dr Varley Dias Sousa, Brasília, DF, Brazil

Dr John Gordon, Wolfville, Nova Scotia, Canada

Professor Jos Hoogmartens, Leuven, Belgium

Mrs Kate Kikule, Kampala, Uganda

Dr François-Xavier Lery, Strasbourg, France

Dr John Miller, Ayr, Scotland

Dr Alain Nicolas, Vandoeuvre, France

0, 2018

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/repor>